From Pathology to Precision: The Story of Leukemia Therapy

Published Date: 26 Mar 2026

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Read Full News

Latest News

Canadian Group Calls for Earlier Colorectal Cancer Screening

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

Todays Updates

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

Todays Updates

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

Latest News

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

News All Time

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

Current treatment options include surgery and chemotherapy, but chemotherapy’s benefits are often modest and can cause substantial side effects.

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Patients with breast cancer living in states with expanded Medicaid eligibility, have seen survival gains, raising more concerns about the impact of recent changes to the program.

Cancer and HIV Vaccines Enter the Therapeutic Era

Therapeutic vaccines are advancing in oncology and HIV, with the aim of retraining immune responses to target tumors and persistent viral reservoirs with precision.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Home Screening Appeals to Women Facing Healthcare Barriers

Researchers asked more than 2000 women if they preferred at-home vaginal self-sampling over clinic-based testing to screen for cervical cancer.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

Ten-year survival data support salvage focal therapy as an option for patients with localized recurrence after prostate cancer radiotherapy.

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

‘Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Stereotactic Radiation Linked to Better Brain Mets Outcomes

Researchers compared outcomes of stereotactic radiation and hippocampal-avoidance whole brain radiation in patients with 5-20 brain metastases.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

The all-oral, fixed-duration treatment combination provided better PFS and safety than investigator’s choice of chemoimmunotherapy in the phase 3 AMPLIFY study.

Violent Parental Death Raises Mortality Risk in Kids

Parental death from violent or preventable causes may signal a need for earlier, targeted interventions to reduce downstream health risks in children.

Recommended News For You

Parkinson patient's gait is restored by a spinal cord stimulator.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

AI could help improve early detection of interval breast cancers

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

Exercise may help breast cancer survivors manage weight

Recommended Articles For You

Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After  

Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification 

The Latest Research on Acute Promyelocytic Leukemia: Advancements in Diagnosis and Therapy  

Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mapping lifelong chronic health risks for childhood cancer survivors

2.

High weight and obesity are associated with poor outcomes in leukemia treatment.

3.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

4.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

5.

Housing aid linked to lower medical financial hardship among US renters with cancer

1.

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment

2.

Exploring the Latest Treatments for Desmoid Tumors

3.

Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL

4.

The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide

5.

Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

4.

Navigating the Complexities of Ph Negative ALL - Part VIII

5.

Navigating the Complexities of Ph Negative ALL - Part XII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot